Incretin Hormones: The Science Behind GIP and GLP-1

Discovery of the Incretin Effect

The incretin effect — the observation that oral glucose produces a greater insulin response than intravenous glucose delivering the same glycemic excursion — was first quantified in the 1960s. Early investigators recognized that gut-derived factors must communicate nutrient arrival to the pancreas ahead of, or in addition to, the glucose signal itself.

GIP: The First Incretin (1970s)

Glucose-dependent insulinotropic polypeptide (originally named "gastric inhibitory polypeptide") was isolated by John Brown and colleagues in the early 1970s from porcine intestinal extracts. Key milestones:

• 1971: GIP isolated and sequenced (42 amino acids)
• 1973: Insulinotropic activity of GIP demonstrated
• 1987: Human GIP receptor cloned
• 1993: GIP receptor knockout mice generated, confirming physiological role

GLP-1: Discovery Through Proglucagon (1980s)

Glucagon-like peptide-1 was discovered not through classical biochemical fractionation but through molecular biology:

• 1982–1983: Proglucagon gene sequenced; GLP-1 sequence identified within the transcript
• 1986: Active form GLP-1(7-36)amide identified as the biologically active truncation
• 1987: Joel Habener and colleagues demonstrate that GLP-1(7-36)amide is more potent than GIP in stimulating insulin secretion
• 1992: GLP-1 receptor cloned
• 1996: First GLP-1 receptor agonist (exendin-4, from Gila monster venom) enters development

Secretion Patterns: K-Cells vs L-Cells

GIP: K-Cell Secretion

GIP is produced by K-cells (enteroendocrine cells expressing the GIPR gene) concentrated in:

• Duodenum (highest density)
• Proximal jejunum
• Lesser amounts in distal small intestine

Secretion triggers:

• Fat: most potent GIP secretagogue (long-chain fatty acids, monoglycerides)
• Carbohydrates: glucose and fructose via SGLT1 and GLUT5 sensing
• Protein: amino acids and dipeptides via PepT1-linked sensing

Kinetics: GIP rises within 15 minutes of meal initiation, peaks at 30–60 minutes, returns to baseline by 3–4 hours.

GLP-1: L-Cell Secretion

GLP-1 is produced by L-cells (expressing proglucagon under intestinal transcription factor control) concentrated in:

• Distal ileum (highest density)
• Colon and rectum
• Scattered cells in proximal gut

Secretion triggers:

• Nutrient contact with distal gut (fat, carbohydrate, protein)
• Neural signaling: vagal cholinergic input and enteric neurons can trigger "early-phase" GLP-1 secretion before nutrients reach distal bowel
• Short-chain fatty acids (from colonic fermentation of fiber)
• Bile acids: via TGR5 receptor on L-cells

Kinetics: GLP-1 shows a biphasic secretion pattern:

1. Early phase (15–30 min): Neurally mediated, independent of direct nutrient contact
2. Late phase (60–120 min): Nutrient-driven from distal L-cells

The Incretin Effect: Healthy vs. Type 2 Diabetes

In Healthy Subjects

The incretin effect (the fraction of postprandial insulin secretion attributable to incretin hormones) accounts for 50–70% of total insulin released after oral glucose in healthy individuals. GLP-1 and GIP contribute approximately equally under normal conditions.

In Type 2 Diabetes

A landmark finding in T2D research is the loss of the incretin effect:

• Incretin contribution to insulin secretion falls to <20% in T2D
• GLP-1 secretion itself is relatively preserved (some studies show modest reduction)
• GLP-1 receptor responsiveness is partially maintained in T2D beta cells
• GIP secretion is also relatively preserved
• GIP receptor responsiveness is severely impaired in T2D beta cells

This dissociation has important implications:

1. GLP-1 agonists retain substantial efficacy in T2D because GLP-1R responsiveness persists
2. GIP agonism alone is ineffective in T2D (impaired GIPR on beta cells)
3. However, GIPR agonism at supraphysiological doses (as with tirzepatide) may overcome beta cell GIPR resistance

Native GLP-1 Half-Life: The Problem of DPP-4 Cleavage

Native GLP-1(7-36)amide has a plasma half-life of less than 2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4), an enzyme expressed on endothelial cells, kidney brush border, and circulating lymphocytes.

DPP-4 cleaves the His-Ala dipeptide from the N-terminus, generating GLP-1(9-36)amide — an inactive or weakly antagonistic fragment.

How Pharmacological Agonists Overcome This

Three strategies have been used to create stable GLP-1 receptor agonists:

1. Exendin-4-based peptides (exenatide, exendin-4)

• Naturally occurring in Gila monster venom
• Position 2 substitution (Gly instead of Ala): DPP-4 resistant
• Half-life: ~2.4 hours (exenatide), ~weeks (exenatide LAR)

2. GLP-1 analogs with fatty acid conjugation (liraglutide, semaglutide)

• Liraglutide: C16 fatty acid on Lys26, Arg34 substitution; ~13 hour half-life
• Semaglutide: C18 fatty diacid via linker; Aib8 substitution for DPP-4 resistance; ~1 week half-life via albumin binding

3. Tirzepatide: dual agonist with GIP-based scaffold

• Tirzepatide is built on a GIP analog scaffold with a C20 fatty diacid linker
• Position 2 (Ala→Aib): DPP-4 resistant
• Half-life: ~5 days
• Balanced GLP-1R and GIPR agonist activity

Research Significance

The incretin system represents one of the most therapeutically productive areas in modern metabolic pharmacology. Understanding the cell biology of K-cells and L-cells, the molecular pharmacology of GLP-1R and GIPR, and the pathophysiology of incretin deficiency in T2D provides the conceptual framework for interpreting all GLP-1-based drug research.

peptidescientists.com provides research-grade incretin peptides and agonists for mechanistic endocrinology research.